Skip to Main content Skip to Navigation
Journal articles

Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Abstract : Background The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF V600-mutant advanced melanoma, as previously reported in the coBRIM study. In this Article, we report updated effi cacy results, including overall survival and safety after longer follow-up, and selected biomarker correlative studies.
Document type :
Journal articles
Complete list of metadatas

Cited literature [29 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01407426
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, December 2, 2016 - 10:21:34 AM
Last modification on : Friday, June 19, 2020 - 3:08:49 AM
Long-term archiving on: : Tuesday, March 21, 2017 - 9:28:01 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

  • HAL Id : inserm-01407426, version 1

Collections

Citation

Paolo Ascierto, Grant Mcarthur, Brigitte Dréno, Victoria Atkinson, Gabrielle Liszkay, et al.. Cobimetinib combined with vemurafenib in advanced BRAF V600 -mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, Elsevier, 2016, 17, pp.1248-1260. ⟨inserm-01407426⟩

Share

Metrics

Record views

177